June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The Aldehyde Trap NS2 Reduces Ocular Inflammation in an Endotoxin-Induced Model in Rats
Author Affiliations & Notes
  • Kenneth J Mandell
    Aldeyra Therapeutics, Lexington, MA
  • Scott L Young
    Aldeyra Therapeutics, Lexington, MA
  • Todd C Brady
    Aldeyra Therapeutics, Lexington, MA
  • Footnotes
    Commercial Relationships Kenneth Mandell, Aldeyra Therapeutics (C); Scott Young, Aldeyra Therapeutics (E); Todd Brady, Aldeyra Therapeutics (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3095. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Kenneth J Mandell, Scott L Young, Todd C Brady; The Aldehyde Trap NS2 Reduces Ocular Inflammation in an Endotoxin-Induced Model in Rats . Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3095.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: NS2 is an investigational drug in development for acute noninfectious anterior uveitis and other ocular indications. The mechanism of action of NS2 involves neutralizing toxic free-aldehydes, which are mediators of inflammatory disease, both in the eye and elsewhere. The purpose of this study was to evaluate efficacy of a topical NS2 eye drop formulation in a rat model of ocular inflammation.

Methods: Ocular inflammation was induced in Lewis rats by foot pad injection of lipopolysaccharide (LPS). Thirty (30) female Lewis rats were split in 3 groups to receive topical NS2 0.5%, balanced salt solution (BSS) or dexamethasone 0.1% (DEX) at 1, 3, 7, 10 and 17 hours post-induction. Ocular exams were performed at 24 hours post-induction and scored using a combined Combined Draize and McDonald-Shadduck scoring system. Animals were euthanized to collect ocular tissues, and levels of inflammatory markers ICAM-1 (Intercellular Adhesion Molecule 1), IL-6 (Interleukin 6) and MCP-1 (Monocyte Chemoattractant Protein 1) were measured from retina-choroid specimens by enzyme-linked immunosorbent assay (ELISA).

Results: The mean total ocular examination (OE) scores at 24 hours post-LPS induction were 21.4, 10.1 and 15.7 for the topical BSS, DEX and NS2 groups, respectively. These reductions in mean total OE scores were statistically significant for both NS2 and DEX relative to the BSS control. Similarly, scores for individual components of the OE revealed similar trends with statistically significant reductions observed for conjunctival hyperemia, iris hyperemia and anterior chamber flare for both NS2 and DEX. Statistically significant reductions in ICAM-1 levels were observed for both NS2 and DEX relative to BSS. However, a statistically significant reduction in IL-6 was observed only for NS2. MCP-1 levels could not be detected in any group.

Conclusions: Together these findings provide symptomatic and biochemical evidence of the anti-inflammatory effects of the aldehyde trap NS2 in a model of inflammatory eye disease. The production of toxic aldehydes is mechanistically linked to uveitis and a variety of other inflammatory ocular diseases. The ability of NS2 to trap and sequester free-aldehydes may prove to be a novel mechanism for the treatment of ocular inflammatory diseases.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×